Lyndra Therapeutics Presents Data on Long-Acting Oral Weekly Risperidone (LYN-005) at American Society of Clinical Psychopharmacology 2023 Annual Conference
Additionally:
- Additionally:
The simulated minimum steady-state blood plasma concentration of risperidone for people taking oral weekly risperidone (LYN-005) doses of 15, 30, and 45 mg maintained effective concentrations. - No apparent trend was observed between simulated average steady-state blood plasma concentrations with oral weekly risperidone and symptoms as measured by PANSS score.
- Lyndra’s long-acting oral weekly risperidone is designed to enable a week-long dose of risperidone to be delivered in a single oral capsule.
- Currently, the only long-acting medicines available for schizophrenia require injections, and data show that they are used by a minority of patients.